Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Vertex Pharmaceuticals Incorporated ... VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed ... Moreover, its experimental cell therapy for type 1 diabetes, Zimislecel (formerly VX-880), has shown remarkable ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...

Working with CRISPR Therapeutics, Vertex has hit the ground running with Casgevy, its gene therapy for blood disorders. Moreover, its experimental cell therapy for type 1 diabetes, Zimislecel ...